MedTrace Logo

A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

NCT00717938 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2017-08-25

No results posted yet for this study

Summary

The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.

Conditions

Interventions

DRUG

cisplatinum or carboplatin and e.g.etoposide.

Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.

DRUG

cisplatinum or carboplatin and e.g.etoposide+enoxaparin

Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Lund University Hospital

    lead OTHER

Principal Investigators

  • Lars Ek, MD · University Hospital, Lund

  • Jan Sundberg, RN · University Hospital, Lund

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00717938 on ClinicalTrials.gov